500mg Fulvestrant Versus Exemestane in MBC

500mg Fulvestrant Versus Exemestane in Metastatic Breast Cancer (MBC) Resistant to Adjuvant Non-steroidal Aromatase Inhibitors in Clinical Practice- a Multicenter Retrospective Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03575260

Enrollment

120

Registered

2018-07-02

Start date

2017-07-01

Completion date

2019-01-15

Last updated

2019-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Fulvestrant, Exemestane

Brief summary

500mg Fulvestrant versus Exemestane in MBC

Detailed description

500mg Fulvestrant versus Exemestane in Metastatic Breast Cancer (MBC) resistant to adjuvant Non-steroidal Aromatase Inhibitors in clinical practice- a multicenter retrospective study

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Postmenopausal woman, age \> 18 years old * Diagnosed with ER/PR+，HER2- Metastatic Breast Cancer * Adjuvant treatment of Non-steroidal Aromatase Inhibitors * First line of Metastatic Breast Cancer is 500mg Fulvestrant or Exemestane for at least one month, starting from 2014.01.01-2017.06.01 * Available medical history

Exclusion criteria

* Incomplete medical history

Design outcomes

Primary

Measure	Time frame	Description
PFS	6 weeks	Progression free survival

Secondary

Measure	Time frame
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	6 weeks

Countries

China

Outcome results